Human evidence gets awkward at Frankly Peptides

MOTS-c measured during dialysis

Ninety-four people receiving long-term dialysis, a median follow-up of 26.5 months, and a peptide measured in their blood. I expected a treatment to enter this story somewhere. It never did. The MOTS-c cohort tracked deaths and non-fatal cardiovascular events while researchers studied the patients’ circulating peptide levels.

Dialysis filters blood when the kidneys can no longer do that work adequately. These were people with serious illness, and adding MOTS-c to the researchers’ risk model improved its ability to distinguish outcomes. Nobody received MOTS-c as the experimental treatment.

That is an interesting human finding on its own terms. It leaves the effect of giving the peptide unanswered. The phantom treatment bothers me: the phrase human evidence can place a treatment in the imagination before it has entered an experiment. The MOTS-c article follows that blood measurement into a very different set of muscle experiments.

The strength of a healing tendon

The BPC-157 tendon findings have a satisfying physical quality. In an experiment involving rats with completely cut Achilles tendons, researchers checked mechanical strength, movement and tissue repair. They also grew rat tendon cells in dishes. That is a substantial attempt to examine recovery in the animals, rather than stopping at a change in a molecule.

The human record is much smaller. A safety pilot in two healthy adults reported no adverse events and unchanged safety checks; it did not examine healing in injured patients. Both reactions seem warranted to me: respect for the rat experiment and dissatisfaction with the human gap. BPC-157 deserves both responses.

KPV gels and combination drugs

KPV is a fragment of a hormone, small enough to consist of just three amino acids. Some of its most appealing bowel results involve a surprisingly elaborate journey: nanoparticles carrying KPV inside a protective gel reached inflamed colon tissue in mice.

Another experiment combined KPV with an immunosuppressant in nanoparticles. The mouse findings concern those preparations. Removing the carrier or the other drug changes the intervention being discussed. Protective engineering exposes the work concealed by a short ingredient name. KPV’s delivery experiments are worth that closer look.

Survival after sepsis

Thymosin alpha-1 has a much longer human research history. Its large placebo-controlled sepsis trial enrolled 1,106 adults across 22 centres. At 28 days, mortality was 23.4% with the peptide and 24.1% with placebo, with no statistically significant difference.

Here people really did receive a treatment, and the result was disappointing. That makes a useful counterweight to the temptation to treat the other peptides’ missing trials as if favourable answers were waiting inside them. The thymosin alpha-1 article follows the earlier hopes and the later test.

I’m impatient for actual recovery; reassuring peptide language comes much more easily. The comparison brings those different outcomes together; the questions page tackles the practical claims that remain unsettled.